NKI researchers discover two new drug resistance mechanisms of BRCA1 breast cancer


Breast cancer that developed because of an error in the 'cancer gene' BRCA1 can usually be treated quite well with the drug cisplatin and/or PARP inhibitors. But sometimes the tumor does not respond to these drugs, or it becomes resistant to them during the treatment. Why does this happen? The research group of Netherlands Cancer Institute (NKI) researcher Jos Jonkers has discovered two previously unidentified ways in which breast tumors can harbor resistance against cisplatin and PARP-inhibitors.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.